Get started
SANGAMO THERAP.INC.DL-,01SANGAMO THERAP.INC.DL-,01SANGAMO THERAP.INC.DL-,01

SANGAMO THERAP.INC.DL-,01

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals

GBY chart


Full chart

GBY upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪155.62 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.4981 EUR
Net income (FY)
‪−94.61 M‬ EUR
Revenue (FY)
‪55.83 M‬ EUR
Shares float
‪214.84 M‬
Beta (1Y)
1.83

Employees


Employees (FY)
183
Change (1Y)
−222 −54.81%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Sangamo Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander D. Macrae
Website
sangamo.com
Headquarters
Richmond
Founded
1995
FIGI
BBG000BG4CH2
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GBY news



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as GBY.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on MUN exchange SANGAMO THERAP.INC.DL-,01 stocks are traded under the ticker GBY.
We've gathered analysts' opinions on SANGAMO THERAP.INC.DL-,01 future price: according to them, GBY price has a max estimate of 9.14 EUR and a min estimate of 1.83 EUR. Watch GBY chart and read a more detailed SANGAMO THERAP.INC.DL-,01 stock forecast: see what analysts think of SANGAMO THERAP.INC.DL-,01 and suggest that you do with its stocks.
GBY reached its all-time high on Sep 1, 2000 with the price of 54.7000 EUR, and its all-time low was 0.2819 EUR and was reached on Nov 13, 2023. View more price dynamics on GBY chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track SANGAMO THERAP.INC.DL-,01 financials in yearly and quarterly reports right on TradingView.
SANGAMO THERAP.INC.DL-,01 is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
GBY earnings for the last quarter are −0.11 EUR per share, whereas the estimation was −0.088 EUR resulting in a −20.55% surprise. The estimated earnings for the next quarter are −0.11 EUR per share. See more details about SANGAMO THERAP.INC.DL-,01 earnings.
SANGAMO THERAP.INC.DL-,01 revenue for the last quarter amounts to ‪7.29 M‬ EUR, despite the estimated figure of ‪11.30 M‬ EUR. In the next quarter, revenue is expected to reach ‪8.23 M‬ EUR.
GBY net income for the last quarter is ‪−22.60 M‬ EUR, while the quarter before that showed ‪8.43 M‬ EUR of net income which accounts for −368.12% change. Track more SANGAMO THERAP.INC.DL-,01 financial stats to get the full picture.
No, GBY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 28, 2025, the company has 183 employees. See our rating of the largest employees — is SANGAMO THERAP.INC.DL-,01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SANGAMO THERAP.INC.DL-,01 EBITDA is ‪−86.72 M‬ EUR, and current EBITDA margin is −155.31%. See more stats in SANGAMO THERAP.INC.DL-,01 financial statements.
Like other stocks, GBY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANGAMO THERAP.INC.DL-,01 stock right from TradingView charts — choose your broker and connect to your account.